Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?

被引：31

作者：

Hanley, Colleen M. ^{[1
]}

Kowey, Peter R. ^{[2
,3
]}

机构：

[1] Lankenau Med Ctr, Wynnewood, PA 19096 USA

[2] Lankenau Inst Med Res, Chair Cardiovasc Res, Main Line Hlth Hosp, Div Cardiovasc Dis, Philadelphia, PA USA

[3] Jefferson Med Coll, Med & Clin Pharmacol, Philadelphia, PA USA

来源：

JOURNAL OF THORACIC DISEASE | 2015年 / 7卷 / 02期

关键词：

Anticoagulants; atrial fibrillation (AF); hemorrhage; stroke; warfarin; FACTOR XA INHIBITOR; LY RANDOMIZED EVALUATION; RISK-FACTORS; COST-EFFECTIVENESS; DABIGATRAN; THERAPY; STROKE; EDOXABAN; SAFETY; THROMBOEMBOLISM;

D O I：

10.3978/j.issn.2072-1439.2015.01.23

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Atrial fibrillation (AF) is associated with significant morbidity and mortality related to stroke due to thromboembolism. Several novel oral anticoagulants (NOACs) have been developed that dosedependently inhibit thrombin or activated factor X (factor Xa). These new agents offer potential advantages over vitamin K antagonists, however, several limitations exist. We will review the four large randomized trials comparing the efficacy and safety of new oral anticoagulants with warfarin for stroke prevention in patients with AF as well as assess "real world" data and discuss the limitations of the new agents.

引用

页码：165 / 171

页数：7

共 29 条

[1] Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation [J].

Birman-Deych, E ;

Radford, MJ ;

Nilasena, DS ;

Gage, BF .

STROKE, 2006, 37 (04) :1070-1074

[2] Newly Identified Events in the RE-LY Trial [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Reilly, Paul A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1875-1876

[3] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[4] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial [J].

Eikelboom, John W. ;

Wallentin, Lars ;

Connolly, Stuart J. ;

Ezekowitz, Mike ;

Healey, Jeff S. ;

Oldgren, Jonas ;

Yang, Sean ;

Alings, Marco ;

Kaatz, Scott ;

Hohnloser, Stefan H. ;

Diener, Hans-Christoph ;

Franzosi, Maria Grazia ;

Huber, Kurt ;

Reilly, Paul ;

Varrone, Jeanne ;

Yusuf, Salim .

CIRCULATION, 2011, 123 (21) :2363-U72

[5] Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran [J].

Ezekowitz, Michael D. ;

Connolly, Stuart ;

Parekh, Amit ;

Reilly, Paul A. ;

Varrone, Jeanne ;

Wang, Susan ;

Oldgren, Jonas ;

Themeles, Ellison ;

Wallentin, Lars ;

Yusuf, Salim .

AMERICAN HEART JOURNAL, 2009, 157 (05) :805-810

[6] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation [J].

Freeman, James V. ;

Zhu, Ruo P. ;

Owens, Douglas K. ;

Garber, Alan M. ;

Hutton, David W. ;

Go, Alan S. ;

Wang, Paul J. ;

Turakhia, Mintu P. .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) :1-U129

[7] Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents [J].

Fukuda, Toshio ;

Honda, Yuko ;

Kamisato, Chikako ;

Morishima, Yoshiyuki ;

Shibano, Toshiro .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :253-259

[8] Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].

Giugliano, Robert P. ;

Ruff, Christian T. ;

Braunwald, Eugene ;

Murphy, Sabina A. ;

Wiviott, Stephen D. ;

Halperin, Jonathan L. ;

Waldo, Albert L. ;

Ezekowitz, Michael D. ;

Weitz, Jeffrey I. ;

Spinar, Jindrich ;

Ruzyllo, Witold ;

Ruda, Mikhail ;

Koretsune, Yukihiro ;

Betcher, Joshua ;

Shi, Minggao ;

Grip, Laura T. ;

Patel, Shirali P. ;

Patel, Indravadan ;

Hanyok, James J. ;

Mercuri, Michele ;

Vogelmann, O. ;

Gonzalez, C. ;

Ahuad Guerrero, R. ;

Rodriguez, M. ;

Albisu, J. ;

Rosales, E. ;

Allall, O. ;

Reguero, M. ;

Alvarez, C. ;

Garcia, M. ;

Ameriso, S. ;

Ameriso, P. ;

Amuchastegui, M. ;

Caceres, M. ;

Beloscar, J. ;

Petrucci, J. ;

Berli, M. ;

Budassi, N. ;

Valle, M. ;

Bustamante Labarta, G. ;

Saravia, M. ;

Caccavo, A. ;

Fracaro, V. ;

Cartasegna, L. ;

Novas, V. ;

Caruso, O. ;

Saa Zarandon, R. ;

Colombo, H. ;

Morandini, M. ;

Cuello, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104

[9] Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study [J].

Go, Alan S. ;

Fang, Margaret C. ;

Udaltsova, Natalia ;

Chang, Yuchiao ;

Pomernacki, Niela K. ;

Borowsky, Leila ;

Singer, Daniel E. .

CIRCULATION, 2009, 119 (10) :1363-1369

[10] Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].

Granger, Christopher B. ;

Alexander, John H. ;

McMurray, John J. V. ;

Lopes, Renato D. ;

Hylek, Elaine M. ;

Hanna, Michael ;

Al-Khalidi, Hussein R. ;

Ansell, Jack ;

Atar, Dan ;

Avezum, Alvaro ;

Cecilia Bahit, M. ;

Diaz, Rafael ;

Easton, J. Donald ;

Ezekowitz, Justin A. ;

Flaker, Greg ;

Garcia, David ;

Geraldes, Margarida ;

Gersh, Bernard J. ;

Golitsyn, Sergey ;

Goto, Shinya ;

Hermosillo, Antonio G. ;

Hohnloser, Stefan H. ;

Horowitz, John ;

Mohan, Puneet ;

Jansky, Petr ;

Lewis, Basil S. ;

Luis Lopez-Sendon, Jose ;

Pais, Prem ;

Parkhomenko, Alexander ;

Verheugt, Freek W. A. ;

Zhu, Jun ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992

← 1 2 3 →